ClinicalTrials.gov
public full text
Public Domain
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of KY1005 in Healthy Volunteers#1137580
- A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis#844929
- A Study of IBI353 (Orismilast) in Chinese Healthy Adults#903607
- Clinical Trial Using Humira in Netherton Syndrome#1060102
- Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741#1170761
Record · ID 1214223
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive